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Abstract 
Purpose: To evaluate the protective effect of melatonin on diabetes-induced cognitive dysfunction.  
Methods: Rats were fed a high-fat diet + streptozotocin (HFD + STZ) for 15 weeks to induce type 2 
diabetes (HFD + STZ group). At the end of the 15-week induction of diabetes, cognitive function in the 
diabetic rats was estimated using a Morris water maze and an object recognition task. Next, the diabetic 
rats were treated with melatonin (10 mg/ kg, po) for 3 weeks. Thereafter, cognitive function was re-
evaluated in the melatonin-treated diabetic rats (melatonin group). 
Results: There was a significant (p < 0.01) decrease in the serum glucose and insulin in melatonin-
treated diabetes type 2 rats compared with that of diabetes type 2 rats exposed to only HFD + STZ. 
Treatment with melatonin (10 mg/kg, po) for 3 weeks in diabetic type 2 rats also caused a significant 
increase (p < 0.01) in the time spent in the target quadrant and preference index in diabetic rats 
compared with the HFD + STZ group. There were significant decreases in reactive oxygen species 
(ROS), oxido-nitrosative stress markers, including thiobarbituric acid reactive substances (TBARS), 
nitrite, and depleted glutathione (GSH) level in the hippocampus of melatonin-treated group, compared 
with the HFD + STZ-treated group. Moreover, the melatonin-treated group showed significant inhibition 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and reduction in the levels of 
proinflammatory cytokines.  
Conclusion: The results demonstrate that melatonin prevents cognitive dysfunction in type 2 diabetic 
rats by attenuating oxido-nitrosative stress and NF-κB-mediated neuroinflammation. This effect 
suggests that melatonin may be useful for the management of cognitive dysfunction in patients suffering 
from diabetes.   
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Diabetes is a metabolic disorder that results from 
inadequate action and secretion of insulin [1]. 
Complications in several body systems, such as 
cranial and peripheral nerves, large vessels, 
eyes, kidney, and cardiovascular system, are 
associated with diabetes [2,3]. Cognitive deficits 
have also been observed in both type 1 and type 
2 diabetes patients.  
 
Previous studies suggest that hyperglycemia is 
associated with the cognitive decline seen in 
both types of diabetic patients [4]. Hyperglycemia 
alters multiple mechanisms, causing activation of 
protein kinase C activity and the polyol pathway, 
accumulation of sorbitol and advanced glycation 
end products, disturbances in Ca2+ homeostasis, 
and augmentation of reactive oxygen species 
(ROS) levels. Increased levels of ROS and free 
radical generation disturb oxidative metabolism 
balance, which leads to detrimental effects on 
cellular function [5]. The detrimental changes 
induced by ROS in the cell include depletion of 
endogenous antioxidants, energy insufficiency, 
mitochondrial dysfunction, protein and DNA 
damage, and inflammation.  
 
Furthermore, oxidative stress causes activation 
of the pleiotropic transcription factor known as 
nuclear factor kappa B-light-chain-enhancer of 
activated B cells (NF-κB). NF-κB activation 
further increases the levels of proinflammatory 
mediators like proinflammatory cytokines 
[cyclooxygenase (COX)-2, inducible nitric oxide 
synthase (iNOS), tumor necrosis factor (TNF)-α, 
and interleukin (IL)-6]. Several studies have 
reported the involvement of NF-κB activation in 
peripheral and central nervous system 
complications of diabetes [6,7].  
 
Melatonin (N-acetyl-5-methoxytryptamine), a 
pineal hormone, is one of the well-studied 
pharmacological interventions that exert 
protective effects primarily by ROS scavenging 
activity. In addition, melatonin augments the 
antioxidant defense system and down-regulates 
inflammatory mediators [8]. Several studies have 
demonstrated the neuroprotective action of 
melatonin in neurodegenerative disorders, such 
as amyotrophic lateral sclerosis, Alzheimer’s 
disease, Parkinson’s disease, and multiple 
sclerosis [9,10]. In a previous study, melatonin 
was found to have a neuroprotective effect 
against streptozotocin (STZ)-induced 
neurobehavioral and neurochemical deficits [11]. 
The aim of the present study was to investigate 
the protective effect of melatonin against 






Male Sprague-Dawley rats (120 - 140 g) were 
used in this study. The animal study was 
approved by Institutional animal ethical 
committee of Tongji Medical College, China (ref. 
no. TMC/2015/03) and performed in accordance 
with the guidelines of the Association for the 
Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC) for 
experimentation and animal use [12].  
 
Induction of diabetes 
 
All the animals were fed with HFD initially for 
fourteen days and thereafter single dose of STZ 
(35 mg/kg, i.p.) was administered to induce 
diabetes. HFD was provided to the animals 
throughout the study period. Rats with serum 
glucose level ≥ 250 mg/dL were considered 
diabetic animals and were further selected for the 
study. All the animals were divided into four 
groups (n = 12) such as control group animals 
received vehicle (p.o.); HFD group animals were 
fed HFD and then given single dose of STZ 
injection. After completion of 15 weeks, vehicle 
was administered (p.o.) for subsequent three 
weeks. HFD + STZ + M 10 mg / kg group of 
animals were fed HFD and then given single 
dose of STZ injection. After completion of 15 
weeks, melatonin (10 mg/kg) was administered 
(p.o.) for subsequent three weeks. M 10 mg/kg 
group of animals were treated with melatonin (10 
mg/kg) for three weeks after completion of 15 
weeks. Object recognition task and Morris water 
maze test were performed on 15th and 18th week. 
 
Morris water maze (MWM) test  
 
Cognitive function in all the animals was 
assessed by MWM test. Circular tank with 60 cm 
of height and 180 cm of diameter was used in the 
study. A platform was placed in the tank 2 cm 
below the water level having the height 38 cm 
and 12.5 cm diameter which was visible to pups. 
Tank was divided into four different quadrants 
and different symbol was placed in the room to 
differentiate the different quadrants of tank. 
Training was given to all the pups for 4 days 
continuously. In each session 4 trials were given 
at an interval of 30 s in which animal was placed 
in any one of quadrant. The pups were kept as 
such for the duration of 20 sec on the platform 
after it climbs on it. The time taken by the pups to 
reach the platform was considered as escape 
latency. However time spent in the target 
quadrant was estimated by removing the stage 
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from the tank and pups were allowed to search 
the platform. 
 
Object recognition task (ORT) 
 
ORT was performed in a black colored wooden 
box (50 × 70 × 50 cm3). The animal was initially 
habituated to the ORT box for 10 min in a day for 
two consecutive days. On 3rd day, the rat was 
placed for 5 min in the ORT box and then, two 
objects of dissimilar appearance (a blue colored 
truncated cone and a cube-shaped white block) 
were kept in two opposite corners of the ORT 
box. Thereafter, the animals were allowed to 
explore ORT box for another 5-min period and 
the time spent in exploring the objects was 
recorded. Thereafter, animals were returned to 
their respective cage. After of duration of 120 
min, the animals were placed in the ORT box for 
5 min, and the objects placed back in the ORT 
box, with the cube-shaped white block used in 
the previous session changed to a novel object 
(an ellipsoid-shaped red colored object). The 
time spent to explore objects was recorded for 5 
min period. The animal was considered to be 
exploring when animal were facing, sniffing, or 
biting the object. ORT box and the objects were 
cleaned thoroughly with alcohol to avoid olfactory 
cues. Cognitive function was evaluated by 
estimating the time spent in the target quadrant, 
preference index. 
 
Assessment of glucose and insulin level in 
rat serum 
 
Blood was collected from the rat in Eppendorf 
tube and serum was separated out by 
centrifuging blood at 4 oC for the duration of 5 
min at 2000 ×. Level of glucose and insulin in the 
serum were determined by glucose oxidase 
method and ELISA kit (Millipore, USA) 
respectively. 
 
Preparation of brain tissue 
 
At the end of protocol all the animals were 
sacrificed by cervical dislocation and 
hippocampus was isolated from the separated 
brain. 50 mM Tris-Hcl of pH 7.4 and 300 mM of 
sucrose was used to homogenate the brain 
tissue for 10 min at 10000 rpm. Supernatant was 
separated out for further study. 
 
Determination of ROS level 
 
ROS level was estimated by adding 50 µl of 
tissue homogenate in 4.85 ml of potassium 
phosphate buffer (100 mmol/L and pH 7.4). The 
mixture was incubated for 15 min with 2′, 7′-
dichlorofluorescindiacetate dye at 37 °C. After 
incubation, mixture was centrifuged at 12,500 g 
for 10 min at 4 °C. The pellet obtained after 
centrifugation was mixed with 5 mL of 100 mmol/ 
LPBS on a vortex at 0 °C and subsequently 
incubated for 60 min at 37 °C. Fluorescence was 
measured at 488 nm for excitation and 525 nm 
for emission. ROS level was calculated as 
picomoles per min per mg of protein. 
 
Assessment of oxido-nitrosative stress 
 
Level of lipid peroxidation (LPO) was determined 
as per the previously reported method in the 
brain tissues. Amount of malondialdehyde (MDA) 
was estimated at 532 nm.  Hippocampal GSH 
content was estimating the absorbance at a 
wave length of 412 nm and the level of GSH was 
articulated as micromoles of GSH per milligram 
of protein. Nitrite level was determined using a 
commercially available Griess reagent 
(containing 0.1 % N-(1-naphthyl) ethylene 
diamine dihydrochloride, 1 % sulfanilamide and 
2.5 % phosphoric acid).Equal amount of sample 
and Griess reagent were mixed and then 
incubated in a dark place. After 15 min, 
absorbance was measured at 540 nm. 
 
Determination of proinflammatory cytokines 
and Brain-derived neurotrophic factor (BDNF) 
 
IL-6 and TNF-α level was determined by Rat 
ELISA kit purchased from Invitrogen Co, 
Carlsbad, CA, USA. Hippocampal BDNF level 
was estimated by BDNF Emax® ImmunoAssay 
System (Promega Corporation, USA). 
Furthermore, Hippocampus was homogenized 
and sonicated in 8 volumes of 0.1 M ice-cold 
PBS buffer (pH 7.4) containing protease inhibitor 
cocktail. The homogenate was centrifuged at 
10,000 rpm for 10 min at 4 °C. The assay was 
carried out with the help of manufacturer’s kit. 
The absorbance was measured at 450 nm in 
ELISA plate reader. 
 
Western blot assay 
 
Hippocampus was homogenized in 500 µL of 
RIPA buffer containing protease and 
phosphatase inhibitor cocktail. Thereafter, 
homogenate was centrifuged at 12,000 g for 20 
min. The supernatant was collected and stored at 
-80 oC for further analysis. The concentration of 
proteins in the sample was measured using 
previously described method. Equal amount of 
protein extracts were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) 
and then separated proteins transferred onto a 
nitrocellulose membrane. The membrane was 
blocked by 3 % bovine serum albumin. 
Thereafter, membranes were incubated with 
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respective primary antibodies for overnight at 4 
oC. Thereafter membranes were washed with 
TBST and then incubated with a horseradish 
peroxidase conjugated antibody for 2 h at room 
temperature. The antigen-antibody-peroxidase 
complexes were visualized using a colored 
reaction with BCIP-NBT. The quantitative 
analysis of bands was carried out with the help of 




Data are expressed as mean ± SEM. Student’s t 
test was used to compare the difference between 
control and diabetic group. One-way analysis of 
variance (ANOVA) followed by post-hoc Tukey 
test was used to compare the various groups. 
Two-way repetitive measure ANOVA followed by 
post-hoc Bonferroni test was used to find the 
differences in MWM acquisition data. P < 0.05 




Body weight, and serum glucose level and 
serum insulin levels  
 
After 15 weeks of diabetes induction, type 2 
diabetic rats had significantly increased body 
weight (p < 0.01) and showed marked (p < 0.01) 
elevation of serum glucose and insulin levels 
compared with the control group (Table 1). 
Treatment with melatonin significantly reduced 
the serum levels of glucose and insulin in type 2 
diabetic rats compared with levels in the diabetic 
control group. 
 
Type 2 diabetes-induced cognitive deficits 
 
Cognitive function was assessed using the 
Morris water maze (MWM) and an object 
recognition task (ORT) to investigate cognitive 
impairment in control and diabetic rats at the 15th 
week of the study protocol. On the first day of the 
MWM trial, there were no significant differences 
between mean escape latencies of control and 
diabetic rats. However, two-way ANOVA 
revealed longer escape latencies on the second 
(p < 0.01), third (p < 0.001), and fourth (p < 0.01) 
days of the acquisition trial by the diabetic group 
compared with the control group. These results 
indicate learning deficits in diabetic rats (Figure 
1A). Furthermore, a probe trial was conducted to 
assess memory retention in diabetic rats. It was 
found that diabetic rats spent significantly (p < 
0.01) less time in the target quadrant than control 
rats, indicating poor memory retention in diabetic 
rats (Figure 1B).  
 
The effect of diabetes on recognition memory 
after the 15th week of diabetes induction was 
assessed using ORT. One-way ANOVA revealed 
that the diabetic rats failed to discriminate 
between familiar and unfamiliar objects placed in 
the ORT box. Consequently, the preference 
index of diabetic group was significantly (p < 
0.01) higher than that in the control group (Figure 
1C). Similar behavioral results were observed 
after the 18th week of diabetic induction. 
 
Melatonin treatment ameliorated cognitive 
deficits  
 
The melatonin (10 mg/kg)-treatment group 
displayed a significant reduction in escape 
latency on the second (p < 0.05), third (p < 0.01), 
and fourth (p < 0.05) days of the trial compared 
with the cisplatin-treated group (Figure 2A). 
Thus, melatonin treatment significantly reversed 
the type 2 diabetes-induced learning deficits. 
Furthermore, impairment in spatial learning 
observed in a probe trial was significantly 
reversed (p < 0.01) in diabetic animals after 
melatonin treatment (Figure 2B). An ORT 
method was used to verify the effect of melatonin 
treatment on memory in rats. The melatonin 
treatment group spent significantly (p < 0.01) 
more time exploring the novel object than 
diabetic rats, indicating improvement in memory 
function after melatonin treatment (Figure 2C). In 
addition, melatonin treatment alone in normal 
rats did not alter the cognitive function. 
 
Melatonin treatment mitigates dioxido-
nitrosative stress  
 
Diabetic rats showed increases in oxidative 
stress as evidenced by a significant rise in levels 
 
Table 1: Effect of melatonin on body weight, serum glucose level, and serum insulin level in a type 2 diabetic rat 
model 
 
Group Body weight (g) Serum glucose (mg/dL) 
Serum insulin 
(ng/mL) 
Control 155±11.3      102±4.7 6.2±0.5 
HFD+STZ   242±15.6## 249±17.8##     9.5±0.65## 
HFD+STZ+M 10 mg/kg   231±13.8## 151±9.3** 0.78±0.2* 
M 10 mg/kg 143±9.2  97.5±3.1**      0.61±0.11** 
Data are expressed as mean ± SEM (n = 6). ##p < 0.01 compared to control group; * p < 0.01 and ** p < 0.01 
compared to diabetic control 









Figure 1: Effect of 15-week type 2 diabetes on (a) mean escape latency, (b) percentage time spent in the target 
quadrant, and (c) recognition memory. Data are expressed as mean ± SEM (n = 6). # p < 0.05, ## p < 0.01 
compared to control group 
 
  (a)        (b) 
 
(c) 
Figure 2: Effect of melatonin treatment on (a) mean escape latency, (b) percentage time spent in the target 
quadrant, and (c) recognition memory in diabetic rats. Data are expressed as mean ± SEM (n = 6). ## p < 0.01 
and ### p < 0.001 compared to control group; * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to diabetic group 
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of ROS (p < 0.01) and malondialdehyde (MDA; p 
< 0.01), and depletion of glutathione (GSH; p < 
0.01) in the hippocampus region (Figure 3). 
However, melatonin treatment was associated 
with significant reduction of oxidative stress by 
reducing MDA (p < 0.01) and ROS (p < 0.01) 
levels in the hippocampus. Moreover, the GSH 
level was markedly (p < 0.01) increased in the 
hippocampus of melatonin-treated diabetic rats 
due to mitigation of oxidative stress by melatonin 
treatment. The nitrite level, an indirect indicator 
of nitrosative stress that was increased (p < 0.01) 
in the diabetic group, was significantly (p < 0.05) 
reduced by melatonin treatment (Figure 3D). 
 
Melatonin treatment alleviated 
neuroinflammation and prevented brain-
derived neurotrophic factor (BDNF) depletion 
 
Diabetic rats showed higher levels of 
hippocampal IL-6 and TNF-α (p < 0.001) than 
normal animals (Figure 4). Treatment with 
melatonin caused a marked reduction in IL-6 (p < 
0.001) and TNF-α (p < 0.05) levels in diabetic 
animals. Thus, melatonin treatment significantly 
alleviated type 2 diabetes-induced neuro-
inflammation in the hippocampus region. 
Furthermore, hippocampal BDNF content was 
significantly (p < 0.001) depleted in the diabetic 
rats compared with control animals. On the other 
hand, melatonin treatment increased (p < 0.01) 
the BDNF level in the hippocampus compared 
with that in diabetic rats without melatonin 
treatment. 
 
Melatonin treatment inhibited NF-κβ 
activation  
 
The results in Figure 5 show that type 2 diabetes 
significantly (p < 0.001) increased the protein 
expression level of NF-κB and phosphorylated 
Iκβ in diabetic animals. Melatonin treatment 
significantly down regulated the NF-κB protein 
expression level (p < 0.001) and phosphorylation 
of Iκβ (p < 0.05) in the diabetic rats. 
 
 
   (a)       (b) 
 
    (c)       (d) 
Figure 3: Effect of melatonin treatment on (a) ROS, (b) MDA, (c) GSH, and (d) nitrite level in the hippocampus of 
diabetic rats. Data are expressed as mean ± SEM (n=6). ### p < 0.001 compared to control group; ** p < 0.01 and 
*** p < 0.001 compared to diabetic group 





   (a)       (b) 
 
(c) 
Figure 4: Effect of melatonin treatment on (a) IL-6, (b) TNF-α, and (c) BDNF levels in the hippocampus of 
diabetic rats. Data are expressed as mean ± SEM (n = 6). ### p < 0.001 compared to control group; * p < 0.05, ** p 




This study evaluated the protective effect of 
melatonin against cognitive dysfunction in type 2 
diabetic rats. Previous experimental reports 
demonstrated that both type 1 and type 2 
diabetes cause cognitive dysfunction via 
alterations in neurovascular and synaptic 
architecture [13]. In this study, an HFD with a 
single low-dose injection of STZ was used to 
induce type 2 diabetes in rats. Cognitive function 
was evaluated in diabetic animals on the 15th 
week as evidenced by MWM and ORT results. 
The results regarding HFD + STZ-induced 
cognitive deficits are supported by previously 
reported studies [21]. Chronic treatment with 
melatonin for 21 days after 15 weeks of inducing 
diabetes significantly reversed the HFD + STZ-
induced cognitive deficits. The observed 
protective effect of melatonin against cognitive 
dysfunction is in accordance with previous 
experimental studies of melatonin [14]. On the 
18th week, HFD + STZ diabetic animals were 
characterized by hyperglycemia and exhibited 
significant learning and memory impairment. 
 
This impairment was coupled with marked 
increases in oxido-nitrosative stress, 
neuroinflammation, NF-κB activation, and BDNF 
depletion in the hippocampus region. Treatment 
with melatonin for 21 days significantly alleviated 
the cognitive deficits by augmentation of BDNF 
levels and attenuation of oxido-nitrosative stress, 
neuroinflammation, and NF-κB in the 
hippocampus. 
 
Hyperglycemia plays a crucial role in the 
pathogenesis of diabetes-induced cognitive 
dysfunction [15]. Hyperglycemia-induced ROS is 
considered a major culprit in the pathogenesis of 
diabetes-associated complications [16]. In the 
brain, ROS-generated oxidative stress disturbs 
the synaptic function and thereby causes 
cognitive impairment [17]. In the present study,  






Figure 5: Effect of melatonin treatment on NF-κB, IκB, and phospho-IκB expression levels in the hippocampus of 
diabetic rats. Results are expressed as mean ± SEM (n = 3). ### p < 0.001 compared to control group; **p < 0.01 
and ***p < 0.001 compared to diabetic group; $p < 0.05 and $$$p < 0.001 compared to IκB 
 
the levels of MDA (a lipid peroxidation marker) 
and nitrite (an indicator of nitrosative stress) were 
elevated in the hippocampus region of the 
 
diabetic group. Increased levels of oxidative 
stress deplete enzymatic and non-enzymatic 
antioxidants levels and disrupt the normal 
functioning of mitochondria, thereby 
exaggerating oxidative stress. The results 
showed that diabetes significantly depleted the 
GSH level in the hippocampus region. Melatonin 
and its metabolites are powerful free radical 
scavengers and augment the expression of 
several antioxidant enzymes [18-20]. In this 
study, melatonin treatment significantly alleviated 
oxidative stress as evidenced by reduction of 
MDA and nitrite level and augmentation of GSH 
level in the hippocampus.  
 
The involvement of the NF-κB cascade in the 
pathogenesis of diabetes-induced complications 
is well documented in previous experimental 
studies [21]. The NF-κB signaling pathway has 
been implicated in a number of 
neurodegenerative diseases as well and it is 
activated by oxidative stress and proinfla-
mmatory cytokines [22]. Under physiological 
conditions, NF-κB remains in an inactive 
condition in the cytoplasm by forming a complex 
with the inhibitory kappa beta (Iκβ) family. 
However, in cases of activation, NF-κBs detach 
from Iκβ and translocate to the nucleus where 
they bind to the κβ sequence of DNA. This bond 
alters the gene expression level of several 
inflammatory mediator proteins, such as IL-6, 
TNF-α, iNOS, and COX-2. These NF-κB induced 
inflammatory mediators eventually cause 
neuronal cell death and cognitive impairment 
[23]. Our results showed up-regulation of NF-κβ 
protein in the hippocampus of diabetic rats 
compared to normal rats. Proinflammatory 
cytokines (IL-6 and TNF-α) were also 
significantly increased in the hippocampus of 
diabetic rats, which indicates profound 
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neuroinflammation. Numerous studies suggest 
that the neuroprotective effect of melatonin is 
mediated by inhibition of the NF-κB cascade [24].  
 
In the present study, similar findings were 
observed after chronic treatment with melatonin. 
Diabetes-induced NF-κB and its associated 
neuroinflammation were significantly reduced 
after 21 days of melatonin treatment. Moreover, 
the results revealed an increased level of nitrite 
in the diabetic animals, which indirectly indicates 
the up-regulation of iNOS level in the 
hippocampus. However, melatonin treatment 
caused marked reduction in the nitrite level of 
diabetic animals. The reduction of nitrite level by 
melatonin is attributed to its reactive nitrogen 





The results of this study demonstrate that 
melatonin prevents cognitive dysfunction in type 
2 diabetic rats by attenuating oxido-nitrosative 
stress and NF-κ-mediated neuroinflammation. 
These results indicate that melatonin can 
potentially be used for the management of 
cognitive dysfunction in patients suffering from 
diabetes. However, further studies are required 






The authors thank the central hospital of wuhan, 
tongji medical college, Huazhong university of 
science and technology, China, for providing the 
facilities for this study. 
 
Conflict of interest 
 
The authors declare that no conflict of interest is 




We declare that this work was done by the 
authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by the authors. Zhang Xuyan 
performed the experiments and wrote the report. 
Ye Jing Ping, Wang Zhongjing, Ding Sheng, Li 
Li, and Yang Fan analyzed data and gave 
comments. Mao Hong designed the project, 
supervised the experiments, and wrote the entire 
manuscript. All authors read and approved the 




1. Hu FB. Globalization of Diabetes: the role of diet, 
lifestyle, and genes. Diabetes Care 2011; 34: 1249-
1257. 
2. Tripathi AS, Mazumdar PM, Chandewar AV. Changes in 
the pharmacokinetic of sildenafil citrate in rats with 
Streptozotocin-induced diabetic nephropathy. J 
Diabetes Metab Disord 2014; 13: 1-6. 
3. Tripathi AS, Mazumdar PM, Chandewar AV. Sildenafil, a 
phosphodiesterase type 5 inhibitor, attenuates diabetic 
nephropathy in STZ-induced diabetic rats. J Basic Clin 
Physiol Pharmacol 2016; 27: 57-62. 
4. Kodl CT, Seaquist ER. Cognitive dysfunction and 
diabetes mellitus. Endocr Rev. 2008; 29: 494-511. 
5. Smith MA, Zhu X, Tabaton M, Liu G, McKeel (Jr) DW, 
Cohen ML et al., Increased iron and free radical 
generation in preclinical Alzheimer disease and mild 
cognitive impairment. J Alzheimers Dis. 2010; 19: 363-
372. 
6. Kuhad A, Bishnoi M, Tiwari V, Chopra K. Suppression of 
NF-kappabeta signaling pathway by tocotrienol can 
prevent diabetes associated cognitive deficits. 
Pharmacol Biochem Behav 2009; 92: 251-259. 
7. Kumar A, Sharma SS. NF-kappaB inhibitory action of 
resveratrol: a probable mechanism of neuroprotection in 
experimental diabetic neuropathy. Biochem Biophys 
Res Commun. 2010; 394: 360-365.  
8. Dugo L, Serraino I, Fulia F, De Sarro A, Caputi AP, 
Cuzzocrea S. Effect of melatonin on cellular energy 
depletion mediated by peroxynitrite and poly (ADP-
ribose) synthetase activation in an acute model of 
inflammation. J Pineal Res. 2001; 31: 76 - 84.  
9. Rosales-Corral SA, Acuña-Castroviejo D, Coto-Montes A, 
Boga JA, Manchester LC, Fuentes-Broto L, Korkmaz A, 
Ma S, Tan DX, Reiter RJ. Alzheimer’s disease: 
pathological mechanisms and the beneficial role of 
melatonin. J Pineal Res. 2012; 52: 167 - 202. 
10. Agil A, Reiter RJ, Jiménez-Aranda A, Ibán-Arias R, 
Navarro-Alarcón M, Marchal JA, Adem A, Fernández 
VG. Melatonin ameliorates low-grade inflammation and 
oxidative stress in young Zucker diabetic fatty rats. J 
Pineal Res. 2013; 54: 381 - 388. 
11. Miller E, Morel A, Saso L, Saluk J. Melatonin redox 
activity. Its potential clinical applications in 
neurodegenerative disorders. Curr Top Med Chem. 
2015; 15:163 - 169. 
12. Guide for the Care and Use of Laboratory Animals: 
Eighth Edition Committee for the Update of the Guide 
for the Care and Use of Laboratory Animals; National 
Research Council. 2010; ISBN: 0-309-15401-4. 
13. Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, 
Liao MX, Ding QL, Hu W, Li JC, Hong H. PPARγ agonist 
pioglitazone reverses memory impairment and 
biochemical changes in a mouse model of type 2 
diabetes mellitus. CNS Neurosci Ther. 2012; 18: 659- 
666. 
Xuyan et al 
2874 
 
14. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, 
Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, 
Arendash GW. Protection against cognitive deficits and 
markers of neurodegeneration by long-term oral 
administration of melatonin in a transgenic model of 
Alzheimer disease. J Pineal Res. 2009; 47: 82 - 96. 
15. Biessels GJ, Koffeman A, Scheltens P. Diabetes and 
cognitive impairment. J Neurol. 2006; 253: 477 - 482. 
16. Raza H, John A, Howarth FC. Increased oxidative stress 
and mitochondrial dysfunction in zucker diabetic rat liver 
and brain, Cell Physiol Biochem. 2015; 35: 1241 - 1251. 
17. Soares E, Prediger RD, Nunes S, Castro AA, Viana SD, 
Lemos C, De Souza CM, Agostinho P, Cunha RA, 
Carvalho E, Fontes Ribeiro CA, Reis F, Pereira FC. 
Spatial memory impairments in a prediabetic rat model. 
Neuroscience 2013; 250: 565 - 577. 
18. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter 
RJ. Melatonin: a potent endogenous hydroxyl radical 
scavenger. Endocr J. 1993; 1:57–60. 
19. Rodriguez C, Mayo JC, Sainz, RM, Antolín I, Herrera F, 
Martín V, Reiter RJ. Regulation of antioxidant enzymes: 
a significant role for melatonin. J Pineal Res 2004; 36: 1 
– 9. 
20. Hardeland R, Tan DX, Reiter RJ. Kynuramines, 
metabolites of melatonin and other indoles: the 
resurrection of an almost forgotten class of biogenic 
amines. J Pineal Res. 2009; 47: 109 - 126.  
21. Patel S, Santani D. Role of NF-kappa B in the 
pathogenesis of diabetes and its associated 
complications. Pharmacol Rep. 2009; 61: 595 - 603. 
22. Mincheva-Tasheva S, Soler RM. NF-κB signaling 
pathways: role in nervous system physiology and 
pathology. Neuroscientist. 2013; 19: 175 - 194. 
23. Yirmiya R, Goshen I. Immune modulation of learning, 
memory, neural plasticity and neurogenesis. Brain 
Behav Immun 2011; 25: 181 - 213. 
24. Beni SM, Kohen R, Reiter RJ, Tan DX, Shohami E, 
Melatonin-induced neuroprotection after closed head 
injury is associated with increased brain antioxidants 
and attenuated late-phase activation of NF-kappaB and 
AP-1.FASEB J. 2004; 18:149-51. 
 
